Market Overview:
The global platinum-based anticancer APIs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel anticancer drugs, and growing focus on personalized medicine. By type, the 50ml segment is expected to account for the largest share of the global platinum-based anticancer APIs market in 2018. By application, NSCLC is expected to account for the largest share of this market in 2018. Geographically, North America is expected to dominate this market in 2018.
Product Definition:
Platinum-based anticancer APIs are a class of drugs used to treat various forms of cancer. They work by interfering with the ability of cancer cells to divide and grow. Platinum-based anticancer therapies are an important part of modern cancer treatment, and can be used alone or in combination with other treatments.
50ml:
50ml is a unit of volume that can be used to measure the concentration of solutions and dispersion. It is most commonly used in laboratories for accurately measuring out precise volumes of reagents, chemicals, solvents or solutions. The term “milliliter” is also sometimes shortened to “ml” especially when referring to dispersion or solution quantities in common usage.
100ml:
100ml is a unit of volume that can be used to measure the concentration of solutions and colloidal particles. It is defined as one-hundredth of a litre or one-tenth of a fluid ounce. The U.S Pharmacopeia has established the International System of Units (ISU) as an accepted system for drug concentration measurement in pharmaceutical formulations, which includes 100 ml as the standard measure for liquid drugs in tablets or capsules formulation.
Application Insights:
The platinum-based anticancer APIs market is segmented based on application into non-small cell lung cancer (NSCLC), ovarian cancer, testicular cancer, and others. The NSCLC segment held the largest share in 2017 owing to the availability of effective therapies for this type of tumor. According to data published by NCBI, in 2018 approximately 160,170 new cases were registered globally each year and around 54% of these cases are diagnosed in Europe & North America regions.
Ovarian Cancer is anticipated to be one of the fastest growing segments during forecast years due to increasing prevalence rates coupled with effectiveness of treatment options such as aromatase inhibitors that are used for treating this disease. Platinum-based compounds have been found effective against ovarian tumors which exhibit resistance towards chemotherapy and hormonal therapy; therefore these compounds act as a potential alternative therapeutic option for treating Ovarian Cancer.
Regional Analysis:
North America dominated the global platinum-based anticancer APIs market in 2017. This is attributed to the presence of key players such as Johnson & Johnson Services, Inc.; Pfizer, Inc.; and Bristol-Myers Squibb Company in this region. Moreover, these companies are also focusing on the development of novel drug molecules that can target different pathways than traditional drugs do. For instance, in January 2018, Bristol-Myers Squibb Company announced about its collaboration with a China based company Sichuan Higher Education Center for Pharmaceutical Sciences (Shenzhen) Co. The company has shown interest to explore this molecule as a treatment option for cancer patients suffering from recurrent glioblastoma multiforme (rGBM).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and increasing prevalence of cancer among people aged 30 years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the platinum-based anticancer APIs market. According to a study by the World Health Organization (WHO), in 2012, there were an estimated 14 million new cases of cancer and 8.2 million deaths from cancer worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. This growing prevalence of cancer is expected to drive the demand for platinum-based anticancer APIs in the coming years.
- Rising awareness about available treatment options: There has been a rise in awareness about available treatment options for various types of cancers in recent years, which is driving demand for platinum-based anticancer APIs. Many patients are now opting for early diagnosis and treatment, which is leading to an increase in demand for these drugs therapies globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Platinum-based Anticancer APIs Market Research Report
By Type
50ml, 100ml, 200ml
By Application
NSCLC, Ovarian Cancer, Testicular Cancer, 其他
By Companies
Nanjing Pharmaceutical Factory, Lingnan Pharmacy, Hansoh Pharma, Bievalley, Yunnan Phytopharmaceutical, Qilu Pharmaceutical, Luoxin, Jinzhou Jiutai Pharmaceutical, Fresenius Kabi, Teva, Cipla, Hospira(Pfizer), Taj Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Platinum-based Anticancer APIs Market Report Segments:
The global Platinum-based Anticancer APIs market is segmented on the basis of:
Types
50ml, 100ml, 200ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
NSCLC, Ovarian Cancer, Testicular Cancer, 其他
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Nanjing Pharmaceutical Factory
- Lingnan Pharmacy
- Hansoh Pharma
- Bievalley
- Yunnan Phytopharmaceutical
- Qilu Pharmaceutical
- Luoxin
- Jinzhou Jiutai Pharmaceutical
- Fresenius Kabi
- Teva
- Cipla
- Hospira(Pfizer)
- Taj Pharmaceuticals
Highlights of The Platinum-based Anticancer APIs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50ml
- 100ml
- 200ml
- By Application:
- NSCLC
- Ovarian Cancer
- Testicular Cancer
- 其他
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Platinum-based Anticancer APIs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Platinum-based anticancer APIs are drugs or other therapies that exploit the platinum coordination complex to kill cancer cells.
Some of the major companies in the platinum-based anticancer apis market are Nanjing Pharmaceutical Factory, Lingnan Pharmacy, Hansoh Pharma, Bievalley, Yunnan Phytopharmaceutical, Qilu Pharmaceutical, Luoxin, Jinzhou Jiutai Pharmaceutical, Fresenius Kabi, Teva, Cipla, Hospira(Pfizer), Taj Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Platinum-based Anticancer APIs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Platinum-based Anticancer APIs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Platinum-based Anticancer APIs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Platinum-based Anticancer APIs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Platinum-based Anticancer APIs Market Size & Forecast, 2020-2028
4.5.1 Platinum-based Anticancer APIs Market Size and Y-o-Y Growth
4.5.2 Platinum-based Anticancer APIs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 50ml
5.2.2 100ml
5.2.3 200ml
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 NSCLC
6.2.2 Ovarian Cancer
6.2.3 Testicular Cancer
6.2.4 其他
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Platinum-based Anticancer APIs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Platinum-based Anticancer APIs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 50ml
9.6.2 100ml
9.6.3 200ml
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 NSCLC
9.10.2 Ovarian Cancer
9.10.3 Testicular Cancer
9.10.4 其他
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 50ml
10.6.2 100ml
10.6.3 200ml
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 NSCLC
10.10.2 Ovarian Cancer
10.10.3 Testicular Cancer
10.10.4 其他
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 50ml
11.6.2 100ml
11.6.3 200ml
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 NSCLC
11.10.2 Ovarian Cancer
11.10.3 Testicular Cancer
11.10.4 其他
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 50ml
12.6.2 100ml
12.6.3 200ml
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 NSCLC
12.10.2 Ovarian Cancer
12.10.3 Testicular Cancer
12.10.4 其他
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 50ml
13.6.2 100ml
13.6.3 200ml
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 NSCLC
13.10.2 Ovarian Cancer
13.10.3 Testicular Cancer
13.10.4 其他
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Platinum-based Anticancer APIs Market: Competitive Dashboard
14.2 Global Platinum-based Anticancer APIs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Nanjing Pharmaceutical Factory
14.3.2 Lingnan Pharmacy
14.3.3 Hansoh Pharma
14.3.4 Bievalley
14.3.5 Yunnan Phytopharmaceutical
14.3.6 Qilu Pharmaceutical
14.3.7 Luoxin
14.3.8 Jinzhou Jiutai Pharmaceutical
14.3.9 Fresenius Kabi
14.3.10 Teva
14.3.11 Cipla
14.3.12 Hospira(Pfizer)
14.3.13 Taj Pharmaceuticals
